Trial reportPharmacotherapy2026
Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post-Anoxic Status Epilepticus.
Trial report in Pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionPost-anoxic status epilepticus (PASE) is a frequent neurologic complication following hypoxic-ischemic brain injury in cardiac arrest survivors, for which no definitive treatment exists. Early γ-Aminobutyric Acid (GABA) augmentation using vigabatrin, a GABA-transaminase inhibitor, has been proposed; however, its pharmacokinetics (PK) in this critically ill population are unknown. In this ancillary study of VIGAB-STAT, an open-label feasibility trial of loading dose vigabatrin via enteral tube, we evaluated vigabatrin PK. MATERIALS AND
methodsComatose adults with electrographic status epilepticus following return of spontaneous circulation received a loading dose of vigabatrin determined by renal function (creatinine clearance (CrCl) ≥ 50 mL/min, 4500 mg; CrCl 30-50 mL/min, 2250 mg; CrCl < 30 mL/min, 1125 mg). Pharmacokinetic sampling occurred at 0 (pre-dose), 0.5, 1, 2, 3, 6, 12, 24, 48, 72, and 168-h post-dose, and plasma concentrations were quantified using liquid chromatography tandem mass spectrometry. PK parameters were estimated using non-compartmental analysis.
resultsSix participants contributed 56 plasma samples. The median (range) age was 62 years (22-68), weight 80.9 kg (57.6-139.9), and four (66.7%) participants were male. Loading doses were evenly distributed: 4500 mg (n = 2), 2250 mg (n = 2), and 1125 mg (n = 2). Time to maximum concentration, maximum concentration, area under the concentration time curve from 0 to 24 h, area under the concentration time curve from 0 to infinity and half-life median (range) values were 2 h (1-3), 38.1 mg/L (16.9-91.8), 431.2 mg*h/L (254.6-979.3), 679.3 mg*h/L (340.3-1156.8), and 16.2 h (9.4-23.9), respectively.
conclusionsThis pioneer vigabatrin PK study in critically ill participants with PASE demonstrated absorption regardless of challenges such as enteral delivery type, co-administration of gastric pH modulators, vasopressors, and anesthetics. Notably, prolonged elimination half-lives and increased exposures were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.